CCorn

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat (RECOMM)

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Condition or disease: Multiple Myeloma
Intervention/treatment: Drug: Farydak

Study Design

Study Type: Observational [Patient Registry]
Estimated Enrollment: 160 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Target Follow-Up Duration: 24 Months
Official Title: A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
Study Start Date: November 2019
Primary Completion Date: November 2021
Study Completion Date: November 2021

Groups and Cohorts

Drug: Farydak
non-interventional study

Outcome Measures

Response to treatment [ Time Frame: 24 months ]
Looking for patient reproted response to treatment with panobinostat

Eligibility Criteria

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample

Study Population

The study population will be any adult who is clinically diagnosed with multiple myeloma who is actively taking panobinostat.

For more information click here